Slide 1: FY 2024 Results: UCB's Decade+ of Growth
FY 2024 Results UCB’s Decade+ of Growth Elevating lives of people through our medicines Capital Market Earnings Call 27 February 2025
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-loo
Slide 3: Agenda
Agenda Proprietary and Confidential Property of UCB Growth Transformative Integrated Closing Strategy Launches Performance Innovations Advancing on Excellence Staying Focused on and Effective our Growth Path in Execution Delivering Results Execution Jean-Christophe Tellier Emmanuel Caeymaex Sandrine
Slide 4: Growth Strategy: Advancing on our Growth Path
Growth Strategy Proprietary and Confidential Property of UCB Advancing on our Growth Path Jean-Christophe Tellier Chief Executive Officer (CEO) UCB - FY results 2024, February 2025 4
Slide 5: Strong Launch Execution Driving Company Growth
SUSTAINABLE GROWTH Strong Launch Execution Driving Company Growth Net sales from the Five Growth Drivers FY 2024 tripled to > € 1.3bn up from €450m in 2023 A year of execution REVENUE -5% REVENUE First and only IL-17A & IL-17F -6% CER +17% inhibitor +19% CER Proprietary and Confidential Property of
Slide 6: Breakthrough Innovation Progress
FY24 HIGHLIGHTS Breakthrough Innovation Progress R&D and Regulatory Achievements 2024 Innovation Progress Industry-leading R&D Productivity DAPIROLIZUMAB PEGOL UCB9741/GALVOKIMIG Atopic Dermatitis Systemic Lupus Erythematosus Positive proof of concept data, Positive results 1st Ph-3, to be presented
Slide 7: Pipeline Progress in 2025 - Important Clinical Development Milestones
OUR INNOVATIVE PIPELINE Pipeline Progress in 2025 - Important Clinical Development Milestones 2025 2026 & BEYOND DOXECITINE & DOXRIBTIMINE UCB9741 / GALVOKIMIG ALPRAZOLAM / STACCATO® Nucleoside therapy – TK2 Deficiency Disorder IL-17A & IL-17F and IL-13 – Atopic Dermatitis Benzodiazepine – Stereotyp
Slide 8: Transformative Launches: Excellence in Execution
Transformative Proprietary and Confidential Property of UCB Launches Excellence in Execution Emmanuel Caeymaex Chief Commercial Officer (CCO) UCB - FY results 2024, February 2025 8
Slide 9: Strong Launch Execution, Expanded Patient Access
Strong Launch Execution, Expanded Patient Access DERMATOLOGY PSORIASIS HIDRADENITIS SUPPURATIVA Our Launch Performance in PSO Launch Performance ≥25% ~9K ~5K HS Approvals HS Patients on BIMZELX® Proprietary and Confidential Property of UCB IL-17 Dynamic Number of Number of Patients > 1 000 market sh
Slide 10: Strong Launch Execution Cross Rheum Patient Populations
RHEUMATOLOGY Strong Launch Execution Cross Rheum Patient Populations RHEUMATOLOGY | PsA • AS • nr-axSpA Our Launch Performance Our Access Performance Patient Numbers > 10 000 Favourable BEFORE As of JAN25 commercial Proprietary and Confidential Property of UCB coverage among A EXCLUDED DSE all IL-17
Slide 11: Strong Launch Execution Around the Globe, Meeting Patients' Needs
Strong Launch Execution Around the Globe, Meeting Patients’ Needs RYSTIGGO® ZILBRYSQ® FINTEPLA® First and only company with differentiated gMG portfolio Proprietary and Confidential Property of UCB >7 600 patients > 20 on treatment (Dec24) > 1 200 in > 30 > 560 in > 30 countries patients* countries*
Slide 12: Integrated Performance: Staying Focused on Delivering Results
Integrated Proprietary and Confidential Property of UCB Performance Staying Focused on Delivering Results Sandrine Dufour Chief Financial Officer (CFO) UCB - FY results 2024, February 2025 12
Slide 13: Strong Launch Execution & Extra-Financial Performance
FY 2024 Strong Launch Execution & Extra-Financial Performance Net Sales of € 5.6 bn: +15%; +17% CER Available for all indications Increased patient reach Launch acceleration leading Launched globally since >900k patients reached* Net sales of € 686m, >€ 2bn net sales in key markets Peak Sales of >€
Slide 14: FY24 Performance Highlights
FY24 Performance Highlights Delivering Topline Growth & Investing behind Execution FY 2024 Actual CER Revenue Net Sales € 5 613m (+15%; +17% CER) - strong launch execution 6 152 17% 19% Other revenue € 461m (+50%; +50%) - sale of rights to 2 established brands, minzasolmin termination Adjusted Margi
Slide 15: 2025 Financial Guidance: Progressing on our Decade+ of Growth
2025 FINANCIAL GUIDANCE Progressing on our Decade+ of Growth Delivering strong growth, innovation and improved profitability Like for like, expected revenue to increase 2025 Financial Guidance** between +14% and +17% y-o-y Underlying top line growth of 14%-17% € 6.5-6.7bn Strong growth driven by
Slide 16: Closing: Innovations and Effective Execution
Closing Proprietary and Confidential Property of UCB Innovations and Effective Execution Jean-Christophe Tellier CEO UCB - FY results 2024, February 2025 16
Slide 17: Breakthrough innovation to elevate lives of people through our medicines
Breakthrough innovation to elevate lives Proprietary and Confidential Property of UCB of people through our medicines Differentiated solutions and cutting-edge pipeline to unlock growth for a decade+ and beyond Breakthrough Innovation & Commitment to delivering value to patients, Execution Excellenc
Slide 18: Proprietary and Confidential Property of UCB
Proprietary and Confidential Property of UCB